Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

Published:2015-09-21 Issue:9 Volume:16 Page:22811-22829
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Polillo Marialuisa,Galimberti Sara,Baratè Claudia,Petrini Mario,Danesi Romano,Di Paolo Antonello

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/16/9/22811/pdf

Reference89 articles.

1. Imatinib mesylate (Gleevec(R)/Glivec(R)): A new therapy for chronic myeloid leukemia and other malignancies

2. How I treat newly diagnosed chronic myeloid leukemia in 2015

3. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

4. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

5. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population;Cancer Chemotherapy and Pharmacology;2024-06-18

2. Genotype influenced pharmacokinetics of anticancer medicine: A connecting link;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

3. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia;Pharmaceutics;2023-10-26

4. Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance;International Journal of Molecular Sciences;2023-09-07

5. Precision medicine: Overview and challenges to clinical implementation;Principles of Gender-Specific Medicine;2023